Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Case study: management of advanced prostate cancer with soft tissue metastases

Prostate Cancer and Prostatic Diseases volume 8, pages 290–292 (2005)Cite this article

Although the outcome following radical prostatectomy is generally favorable, up to one-third of men will experience PSA progression within 10 y. For men whose postoperative PSA level remains at >0.4 ng/ml, as in this case, the PSA progression rate approaches 100%.1 Such patients are at increased risk of developing metastases2 and should be considered for second-line radiotherapy and/or hormonal therapy.

Prostate cancer metastases are most commonly skeletal; pulmonary metastases are usually only seen after bone or lymph node involvement.3 The present case, in which pulmonary metastases developed without detectable disease in the bones or other soft tissue sites, is very rare.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Lange PH et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141: 873–879.

    Article  CAS  Google Scholar 

  2. Rogers CG et al. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 2004; 101: 2549–2556.

    Article  Google Scholar 

  3. Behrakis P, Koutsilieris M . Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy. Anticancer Res 1997; 17: 1517–1518.

    CAS  PubMed  Google Scholar 

  4. Loblaw DA et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22: 2927–2941.

    Article  Google Scholar 

  5. Seidenfeld J et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566–577.

    Article  CAS  Google Scholar 

  6. Cassileth BR et al. Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res 1992; 1: 323–330.

    Article  CAS  Google Scholar 

  7. Iversen P et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579–1582.

    Article  CAS  Google Scholar 

  8. Sieber PR et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272–2276.

    Article  CAS  Google Scholar 

  9. Anderson J . The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455–461.

    Article  CAS  Google Scholar 

  10. Fourcade R-O, McLeod D . Tolerability of antiandrogens in the treatment of prostate cancer. UroOncology 2004; 4: 5–13.

    Article  CAS  Google Scholar 

  11. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491–1498.

  12. Klotz L, Schellhammer P, Carroll K . A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93: 1177–1182.

    Article  CAS  Google Scholar 

  13. Akaza H et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004; 34: 20–28.

    Article  Google Scholar 

  14. Wirth M et al. Response to second-line hormonal therapy following progression on bicalutamide (‘Casodex’) 150 mg monotherapy. Eur Urol Suppl 2004; 3: 58–223.

    Article  Google Scholar 

  15. Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Written permission to publish this case was obtained from the patient concerned. Editorial support was provided by Louise Picken, PhD; financial support for this assistance was provided by AstraZeneca.

Author information

Authors and Affiliations

  1. The Prostate Centre, 32 Wimpole Street, London, WIG 8GT, UK

    Roger Kirby

Authors
  1. Roger Kirby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger Kirby.

Additional information

‘Casodex’ and ‘Zoladex’ are trademarks of the AstraZeneca group of companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirby, R. Case study: management of advanced prostate cancer with soft tissue metastases. Prostate Cancer Prostatic Dis 8, 290–292 (2005). https://doi.org/10.1038/sj.pcan.4500814

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500814

Keywords

Search

Advanced search

Quick links